JP2022505923A - 抗ｔｉｍ－３抗体を投与する方法 - Google Patents

抗ｔｉｍ－３抗体を投与する方法 Download PDF

Info

Publication number
JP2022505923A
JP2022505923A JP2021523009A JP2021523009A JP2022505923A JP 2022505923 A JP2022505923 A JP 2022505923A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2022505923 A JP2022505923 A JP 2022505923A
Authority
JP
Japan
Prior art keywords
seq
tim
antibody
cdr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523009A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020093024A5 (https=
JP2022505923A5 (https=
Inventor
ルイージ，メアリー
ザイナゲットディノフ，リナット
チャン，ドン
ザオ，シンヤン
アン，チー
ナネマン，デイビッド
スード，ヴァニタ，ディー．
イフラント，クリステル
Original Assignee
メルク パテント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク パテント ゲーエムベーハー filed Critical メルク パテント ゲーエムベーハー
Publication of JP2022505923A publication Critical patent/JP2022505923A/ja
Publication of JPWO2020093024A5 publication Critical patent/JPWO2020093024A5/ja
Publication of JP2022505923A5 publication Critical patent/JP2022505923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021523009A 2018-11-01 2019-11-01 抗ｔｉｍ－３抗体を投与する方法 Pending JP2022505923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754378P 2018-11-01 2018-11-01
US62/754,378 2018-11-01
PCT/US2019/059556 WO2020093024A2 (en) 2018-11-01 2019-11-01 Methods of administering anti-tim-3 antibodies

Publications (3)

Publication Number Publication Date
JP2022505923A true JP2022505923A (ja) 2022-01-14
JPWO2020093024A5 JPWO2020093024A5 (https=) 2022-11-08
JP2022505923A5 JP2022505923A5 (https=) 2022-11-08

Family

ID=69159932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523009A Pending JP2022505923A (ja) 2018-11-01 2019-11-01 抗ｔｉｍ－３抗体を投与する方法

Country Status (8)

Country Link
US (1) US20220073616A1 (https=)
EP (1) EP3873612A2 (https=)
JP (1) JP2022505923A (https=)
CN (1) CN113301961A (https=)
AU (1) AU2019372436A1 (https=)
CA (1) CA3117371A1 (https=)
IL (1) IL282708A (https=)
WO (1) WO2020093024A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
CN118255902A (zh) 2017-03-02 2024-06-28 加拿大国家研究委员会 TGF-β受体胞外域融合分子及其用途
MX2023000005A (es) * 2020-06-26 2023-03-06 Sorrento Therapeutics Inc Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
CN117120091A (zh) * 2021-04-13 2023-11-24 免疫医疗有限责任公司 靶向pd-1和tim-3的双特异性抗体
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
CN117545506A (zh) * 2021-06-24 2024-02-09 百时美施贵宝公司 用于治疗疾病的转化生长因子-β配体陷阱
CN116688115B (zh) * 2022-03-18 2024-02-06 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US8841418B2 (en) * 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
EP3099717B1 (en) * 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
MX370807B (es) * 2014-07-11 2020-01-08 Genmab As Anticuerpos que se unen a axl.
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3878465A1 (en) * 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
SG11201903867YA (en) * 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
EA201990743A1 (ru) * 2016-11-29 2019-11-29 Антитела, направленные против белка-3, содержащего т-клеточный иммуноглобулин и муцин (tim-3)
AU2018264455B2 (en) 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof

Also Published As

Publication number Publication date
CA3117371A1 (en) 2020-05-07
EP3873612A2 (en) 2021-09-08
CN113301961A (zh) 2021-08-24
WO2020093024A2 (en) 2020-05-07
WO2020093024A3 (en) 2020-06-04
US20220073616A1 (en) 2022-03-10
IL282708A (en) 2021-06-30
AU2019372436A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
JP7844558B2 (ja) リンパ球における阻害経路の中和
KR102089072B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
KR102714165B1 (ko) 인간 cd137에 결합하는 작동자 항체 및 이의 용도
CN113929782B (zh) 对淋巴细胞中抑制途径的中和
ES2908916T3 (es) Anticuerpos anti-tim-3
JP2022505923A (ja) 抗ｔｉｍ－３抗体を投与する方法
CN110945026B (zh) 仅有重链的抗bcma抗体
JP2022505925A (ja) 抗ｔｉｍ－３抗体
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
CN114981301B (zh) Pd1和vegfr2双结合剂
KR20230116007A (ko) 항-cd30 항체-약물 접합체를 사용한 면역 반응 조절
KR20230050378A (ko) 항-cd73 항체를 사용하여 암을 치료하는 방법
KR20220151172A (ko) 항-gitr 항체 및 이의 용도
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
KR20210131312A (ko) 인간 cd137에 결합하는 항체의 제제 및 이의 용도
CN117203236A (zh) 包含4-1bb和ox40结合蛋白的组合物及其使用方法
HK40059550A (en) Methods of administering anti-tim-3 antibodies
HK40058527A (en) Anti-tim-3 antibodies
WO2024165403A1 (en) Anti-cea antibodies
HK40113788A (zh) 抗cd39抗体及其用途
JP2025532758A (ja) 癌の治療における使用のためのｂｔｎ３ａ活性化抗体、ｂｃｌ２阻害剤及び低メチル化剤の併用
CN117503951A (zh) 一种抗体药物偶联物及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240419